Phase II trial of piperazinedione in patients with advanced or recurrent uterine sarcoma. A Gynecologic Oncology Group study.

Abstract

Twenty patients with advanced or recurrent uterine sarcoma no longer amenable to control with surgery and/or radiotherapy were entered into study by Gynecologic Oncology Group institutions to receive piperazinedione 9 mg/m2 intravenously every 3 weeks. One patient was deemed to be ineligible for study. Among the 19 evaluable patients, only one response was observed, a partial response in a patient with leiomyosarcoma. Adverse effects consisted primarily of myelosuppression and were tolerable. Piperazinedione at the dose and schedule tested appears to have little activity against uterine sarcomas.

• Authors: J T Thigpen, J A Blessing, H D Homesley, N Hacker, S L Curry
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 8 Issue 5 Pg. 350-2 (Oct 1985) ISSN: 0277-3732 [Print] United States
• PMID: 3840643 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Piperazines
• 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione

Topics

• Adult
• Aged
• Drug Evaluation
• Female
• Humans
• Leukopenia (chemically induced)
• Middle Aged
• Piperazines (therapeutic use, toxicity)
• Sarcoma (drug therapy)
• Thrombocytopenia (chemically induced)
• Uterine Neoplasms (drug therapy)